Skip to product information
1 of 1

GeneBio Systems

DEAF1 Polyclonal Antibody

DEAF1 Polyclonal Antibody

SKU:E-AB-16381

Regular price €490,95 EUR
Regular price Sale price €490,95 EUR
Sale Sold out
Shipping calculated at checkout.

Size: 200μL

Storage: Store at -20℃ Valid for 12 months. Avoid freeze / thaw cycles.

Shipping: The product is shipped with ice pack,upon receipt,store it immediately at the temperature recommended.

Exp date: 12 months

Category ID_II: Primary Antibodies

Category ID_III: Polyclonal Antibodies

Abbreviation: DEAF1

Target Synonym: Deaf1;DEAF1 transcription factor;DEAF1;Deformed epidermal autoregulatory factor 1 homolog;Nuclear DEA1 related transcriptional regulator;Nuclear DEAF-1-related transcriptional regulator;NUDR;SPN;Suppressin;Zinc finger MYND domain containing protein 5;Zinc finger MYND domain-containing protein 5;ZMYND5

Research Areas: Cell biology;Epigenetics and Nuclear Signaling

Conjugation: Unconjugated

Host: Rabbit

Species reactivity: Human

Application: IHC

Isotype: IgG

Clonality: Polyclonal

Clone NO.:

UNIProt ID: O75398

Accession:

Background: Suppressin, also known as DEAF1 (deformed epidermal autoregulatory factor 1), SPN, NUDR (nuclear DEAF-1-related transcriptional regulator), or ZMYND5 (zinc finger MYND domain-containing protein 5), is a transcription factor required for embryonic development. Suppressin contains one SAND domain and one C-terminal MYND-type zinc finger. It interacts with LMO4 and CLIM-2, suggesting that it plays a role mediating cell fate and embryonic pattern formation. Suppressin is expressed in a variety of tissues and localizes to the nucleus. Several isoforms exist due to alternative splicing and, depending on the isoform, Suppressin is secreted in some cell types. Secreted Suppressin can function to inhibit cell proliferation, arresting cells in the G0 or G1 phase. Mutations in the gene encoding Suppressin may result in a growth advantage leading to the development and progression of neoplasia. This suggest that Supressin is a potential target for cancer therapy.

Concentration: 1.4 mg/mL

Immunogen: Synthetic peptide of human DEAF1

Buffer: PBS with 0.05% sodium azide and 50% glycerol, PH7.4

Purification method: Affinity purification

Dilution: IHC 1:50-1:200

Calculated MW:

ObservedMW:

View full details